ImmunityBio, Inc. — Form 8-K
Filed July 30, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 42/100
What the filing says
The Emirates Drug Establishment (EDE) granted marketing authorization for ANKTIVA (nogapendekin alfa inbakicept) in two indications: (1) ANKTIVA 0.4 mg with BCG for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) spanning CIS and papillary disease, and (2) ANKTIVA 1.2 mg with checkpoint inhibitors for metastatic NSCLC. This is the UAE's first approval (the fifth regulatory jurisdiction globally) and expands ANKTIVA's footprint to 34 countries. Clinical data showed 71% complete response rate in CIS cohort (N=100) with duration beyond 54 months, 58.2% 12-month disease-free survival in papillary-only cohort (N=80), and 14.6-month median overall survival in NSCLC (N=79).
Why this rating
UAE approval expands geographic reach and validates ANKTIVA across two indications, but represents incremental regulatory progress in a small market. Meaningful for commercial momentum but modest relative to $690M market cap—no material financial impact quantified.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.